Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK),
safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in
healthy subjects.